India's 2nd-largest pharma firm by volume; branded generics, consumer healthcare and specialty-chronic brands.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 40 | 40 | 40 | 40 | 40 | 41 | 41 | 41 |
| Reserves | 3.4k | 4.7k | 6.1k | 7.4k | 9.3k | 14.3k | 15.2k | 16.3k |
| Borrowings | 131 | 241 | 873 | 170 | 207 | 8.5k | 8.4k | 6.3k |
| Other Liabilities | 1.4k | 1.4k | 2.1k | 2.1k | 2.3k | 4.8k | 5.2k | 5.1k |
| Total Liabilities | 5.1k | 6.4k | 9.1k | 9.7k | 11.9k | 27.7k | 28.8k | 27.8k |
| AssetsFixed Assets | 1.6k | 1.7k | 3.6k | 4.3k | 4.5k | 19.0k | 19.3k | 18.6k |
| CWIP | 317 | 372 | 701 | 550 | 282 | 826 | 394 | 1.1k |
| Investments | 829 | 1.5k | 1.1k | 1.3k | 2.6k | 2.0k | 2.9k | 2.0k |
| Other Assets | 2.3k | 2.8k | 3.7k | 3.5k | 4.5k | 5.8k | 6.2k | 6.0k |
| Total Assets | 5.1k | 6.4k | 9.1k | 9.7k | 11.9k | 27.7k | 28.8k | 27.8k |
| Line item | FY15 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | — | 1.1k | 1.1k | 920 | 1.8k | 2.2k | 2.4k | 3.1k |
| Cash from Investing | — | -436 | -1.2k | -1.4k | -1.1k | -2.1k | -12.6k | -181 |
| Cash from Financing | — | -531 | -8 | 605 | -740 | 5 | 10.2k | -3.0k |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | 853 | 826 | -1.4k | 987 | 1.8k | 1.9k | 2.4k |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (48.0×) and current (53.6×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 13.9% growth and a 48× exit, ₹2484 only delivers your return if you pay ₹1,868. The price is currently baking in 20% growth.
EPS grows 13.9%/yr for 5 years, then fades to 6% over 2, exits at 48×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 13.9% | 52.78 |
| FY28 | 13.9% | 60.12 |
| FY29 | 13.9% | 68.47 |
| FY30 | 13.9% | 77.99 |
| FY31 | 13.9% | 88.83 |
| FY32 | 10.0% ·fade | 97.67 |
| FY33 | 6.0% ·fade | 103.53 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.